JP2009526763A - 急性呼吸窮迫症候群の治療 - Google Patents

急性呼吸窮迫症候群の治療 Download PDF

Info

Publication number
JP2009526763A
JP2009526763A JP2008552543A JP2008552543A JP2009526763A JP 2009526763 A JP2009526763 A JP 2009526763A JP 2008552543 A JP2008552543 A JP 2008552543A JP 2008552543 A JP2008552543 A JP 2008552543A JP 2009526763 A JP2009526763 A JP 2009526763A
Authority
JP
Japan
Prior art keywords
surfactant
phospholipid
patient
patients
calfactorant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008552543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526763A5 (fr
Inventor
エイ イーガン，エドマンド
ホルム，ブルース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pneuma Partners LLC
Original Assignee
Pneuma Partners LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/002423 external-priority patent/WO2007084136A2/fr
Application filed by Pneuma Partners LLC filed Critical Pneuma Partners LLC
Publication of JP2009526763A publication Critical patent/JP2009526763A/ja
Publication of JP2009526763A5 publication Critical patent/JP2009526763A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008552543A 2006-01-23 2007-01-23 急性呼吸窮迫症候群の治療 Pending JP2009526763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76125006P 2006-01-23 2006-01-23
PCT/US2006/002423 WO2007084136A2 (fr) 2006-01-23 2006-01-23 Traitement du sras
PCT/US2007/060902 WO2007087524A2 (fr) 2006-01-23 2007-01-23 Traitement de syndromes de detresse respiratoire aigus

Publications (2)

Publication Number Publication Date
JP2009526763A true JP2009526763A (ja) 2009-07-23
JP2009526763A5 JP2009526763A5 (fr) 2010-03-18

Family

ID=38089182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552543A Pending JP2009526763A (ja) 2006-01-23 2007-01-23 急性呼吸窮迫症候群の治療

Country Status (8)

Country Link
EP (1) EP1976535A2 (fr)
JP (1) JP2009526763A (fr)
KR (1) KR20080090442A (fr)
AU (1) AU2007208145A1 (fr)
BR (1) BRPI0706723A2 (fr)
CA (1) CA2637644A1 (fr)
IL (1) IL192121A0 (fr)
WO (1) WO2007087524A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529394A (ja) * 1998-11-10 2002-09-10 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 肺サーファクタント組成物を含有する治療セット
JP2005505607A (ja) * 2001-10-11 2005-02-24 アルタナ　ファルマ　アクチエンゲゼルシャフト 肺サーファクタントの新規使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529394A (ja) * 1998-11-10 2002-09-10 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 肺サーファクタント組成物を含有する治療セット
JP2005505607A (ja) * 2001-10-11 2005-02-24 アルタナ　ファルマ　アクチエンゲゼルシャフト 肺サーファクタントの新規使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5008023905; ＷＩＬＬＳＯＮ　ＤＯＵＧＬＡＳ　Ｆ: ＪＡＭＡ Ｖ２９３　Ｎ４, 20050126, Ｐ４７０-４７６，　９００ *
JPN5008023908; ＨＡＩＴＳＭＡ　Ｊ　Ｊ: ＣＵＲＲＥＮＴ　ＯＰＩＮＩＯＮ　ＩＮ　ＣＲＩＴＩＣＡＬ　ＣＡＲＥ Ｖ１０　Ｎ１, 2004, Ｐ１８-２２ *
JPN5008023911; ＷＩＬＬＳＯＮ　Ｄ: ＥＸＰＥＲＴ　ＯＰＩＮＩＯＮ　ＯＮ　ＰＨＡＲＭＡＣＯＴＨＥＲＡＰＹ Ｖ２　Ｎ９, 200109, Ｐ１４７９-１４９３ *
JPN5008023913; ＮＯＴＴＥＲ　ＲＯＢＥＲＴ　Ｈ: ＣＨＥＭＩＳＴＲＹ　ＡＮＤ　ＰＨＹＳＩＣＳ　ＯＦ　ＬＩＰＩＤＳ Ｖ１１４　Ｎ１, 200201, Ｐ２１-３４ *
JPN6012032525; Ａｍ　Ｊ　Ｐｈｙｓｉｏｌ．，　Ｖｏｌ．２８２　Ｎｏ．４，Ｐｔ．１　ｐ．Ｌ８０３-Ｌ８１０　（２００２） *
JPN6012032527; 日本小児保健学会講演集，　Ｖｏｌ．５１ｓｔ　ｐ．４７　（２００４） *

Also Published As

Publication number Publication date
AU2007208145A1 (en) 2007-08-02
EP1976535A2 (fr) 2008-10-08
WO2007087524A2 (fr) 2007-08-02
CA2637644A1 (fr) 2007-08-02
IL192121A0 (en) 2008-12-29
WO2007087524A3 (fr) 2007-10-18
KR20080090442A (ko) 2008-10-08
BRPI0706723A2 (pt) 2011-04-05

Similar Documents

Publication Publication Date Title
Spragg et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant
Abrams et al. Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study
Wiswell et al. Bronchopulmonary segmental lavage with surfaxin (KL4-surfactant) for acute respiratory distress syndrome
JP2020002144A (ja) 小児における急性呼吸促迫症候群の治療のための吸入一酸化窒素ガスを使用する方法
Guervilly et al. Prone positioning during veno-venous extracorporeal membrane oxygenation for severe acute respiratory distress syndrome in adults
Suresh et al. Current surfactant use in premature infants
JP2020502242A (ja) 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物
Spragg Surfactant replacement therapy
RU2533450C9 (ru) Терапевтическая комбинация, содержащая легочный сурфактант и стероид
Lam et al. Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome
US20070244045A1 (en) Treatment of Acute Respiratory Distress Syndrome
Khan et al. Experience with treatment of pulmonary alveolar proteinosis from a tertiary care centre in north India
Yang et al. Clinical application of extracorporeal membrane oxygenation in children with refractory cardiopulmonary failure
JP2009526763A (ja) 急性呼吸窮迫症候群の治療
Berry et al. Comparison of the effect of three doses of a synthetic surfactant on the alveolar-arterial oxygen gradient in infants weighing≥ 1250 grams with respiratory distress syndrome
AU2002338882B2 (en) Novel use of pulmonary surfactant
RU2149015C1 (ru) Способ лечения постнатальных пневмоний у новорожденных
WO2007084136A2 (fr) Traitement du sras
Vahdatpour et al. A case report of severe hypothermia complicated by acute respiratory distress syndrome
Turell Advances with surfactant
RU2149017C1 (ru) Способ лечения дыхательной недостаточности при критических состояниях у детей
Pacifici Effects of surfactants on preterm infant lungs
Arabi et al. Supplemental Online Content
Nga et al. Late surfactant replacement therapy and its efficacy on severe bronchopulmonary dysplasia in National Children Hospital
Domingos Corrêa et al. Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infection.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100125

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20100311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121225